|
|
 | | | |
- close
- close
- close
- close
FiercePharma
4 hrs ago
Comment
Novartis' blood pressure Diovan is on the wane as its expects generics next quarter to begin eating at its blockbuster status. But even as it comes under attack by generics, so does its reputation, as a probe by Novartis reveals that not...
Market Intelligence Center
7 hrs ago
Comment
Novartis AG (NYSE: NVS) closed Thursday's trading session at $73.82. In the past year, the stock has hit a 52-week low of $51.35 and 52-week high of $75.73. Novartis AG (NVS) stock has been showing support around $72.59 and resistance in the...
Forbes
May 23
Comment
Novartis has acknowledged that employees of the company participated in five "independent" investigator-initiated post-registration trials without disclosing their relationship to the company. The company said that a broader "comprehensive...
FierceBiotech
May 22
Comment
According to an analysis by Bloomberg, Novartis is interested in finding a competitive Alzheimer's drug program. But it's hard to determine from the story if the pharma giant--always reluctant to detail partnering efforts or in-house...
Market Intelligence Center
May 17
Comment
Novartis AG (NYSE: NVS) closed Thursday's trading session at $75.01. In the past year, the stock has hit a 52-week low of $51.20 and 52-week high of $75.67. Novartis AG (NVS) stock has been showing support around $74.46 and resistance in the...
FiercePharma
May 16
Comment
Actavis has suddenly become the belle of the ball. The Wall Street Journal reports that Novartis is now entertaining a $16 billion bid for the generics maker after a $13 billion offer from Valeant and a $15 billion bid from Mylan both fell flat.
FiercePharma
May 16
Comment
Novartis prevailed in the latest court battle over jawbone injuries in Zometa patients. The company did properly warn patients about the drug's risks, a New Jersey jury determined after a 13-day trial.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
| |||||||
